Aktienanalyse zu Palvella Therapeutics Inc (PVLA)PVLAPalvella Therapeutics Inc

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations. It operates in the Healthcare sector.

Palvella Therapeutics is not a good buy right now due to its current price of $120.30, which is significantly below the analyst price targets of $240 and $246. However, the stock has recently experienced a 13.31% decline over the past five days and an RSI of 29.83, indicating it is oversold. The main risk is the company's ongoing losses, with a projected net income loss of $21.87 million in Q2 2026, which raises concerns about its profitability and future funding needs.